<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
---------------------
Date of Report (Date of earliest
event reported)
July 6, 2000 (July 6, 2000)
AFFYMETRIX, INC
-----------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-28218 77-0319159
------------------ ------------------------ --------------------
(State of (Commission File Number) (IRS Employer
incorporation) Identification No.)
3380 Central Expressway, Santa Clara, California 95051
-------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(408) 731-5000
-------------------------------
(Registrant's telephone number,
including area code)
N/A
-------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
-1-
<PAGE>
Items 1-4.
Not Applicable.
Item 5. OTHER EVENTS.
Affymetrix, Inc. (the "Company") announced on July 6, 2000 that PE
Corporation filed suit against the Company in the Federal District Court in
Delaware based on several patents related to reagents the Company purchases
from PE licensed vendors.
The Company stated that it purchases its reagents from licensed vendors
and, therefore, believes that it has meritorious defenses to the claims in
this lawsuit.
All statements in this report that are not historical are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding the
Company's "expectations," "beliefs," "hopes," "intentions," "strategies" or
the like. Such statements are subject to risks and uncertainties that could
cause actual results to differ materially for the Company from those
projected, including, but not limited to, uncertainties relating to
technological approaches, product development, manufacturing, market
acceptance, uncertainties related to cost and pricing of the Company's
products, dependence on collaborative partners, uncertainties relating to
sole source suppliers, uncertainties relating to FDA and other regulatory
approvals, competition, risks relating to intellectual property of others and
the uncertainties of patent protection and litigation. These and other risk
factors are discussed in the Company's Quarterly Report on Form 10-Q for the
quarter ended March 31, 2000. The Company expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in the
Company's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
Item 6. RESIGNATIONS OF REGISTRANT'S DIRECTORS.
Not Applicable.
Item 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) Not Applicable.
(b) Not Applicable.
(c) Not Applicable.
Item 8. CHANGE IN FISCAL YEAR.
Not Applicable.
Item 9. SALES OF EQUITY SECURITIES PURSUANT TO REGULATION S.
Not Applicable.
-2-
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
AFFYMETRIX, INC.
By: /s/ KENNETH NUSSBACHER
-------------------------------------
Name: Kenneth Nussbacher
Title: Executive Vice President
Date: July 6, 2000
-3-
